TAC3

Last updated
TAC3
Available structures
PDB Ortholog search: PDBe RCSB
Identifiers
Aliases TAC3 , HH10, NKB, NKNB, PRO1155, ZNEUROK1, tachykinin 3, tachykinin precursor 3, NK3, LncZBTB39
External IDs OMIM: 162330 MGI: 98476 HomoloGene: 7560 GeneCards: TAC3
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001006667
NM_001178054
NM_013251

NM_001199971
NM_009312

RefSeq (protein)

NP_001171525
NP_037383

NP_001186900
NP_033338

Location (UCSC) Chr 12: 57.01 – 57.03 Mb Chr 10: 127.72 – 127.73 Mb
PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

Tachykinin-3 is a protein that in humans is encoded by the TAC3 gene. [5] [6] [7]

Contents

See also

Related Research Articles

Substance P Chemical compound

Substance P (SP) is an undecapeptide member of the tachykinin neuropeptide family. It is a neuropeptide, acting as a neurotransmitter and as a neuromodulator. Substance P and its closely related neurokinin A (NKA) are produced from a polyprotein precursor after differential splicing of the preprotachykinin A gene. The deduced amino acid sequence of substance P is as follows:

Tachykinin peptides

Tachykinin peptides are one of the largest families of neuropeptides, found from amphibians to mammals. They were so named due to their ability to rapidly induce contraction of gut tissue. The tachykinin family is characterized by a common C-terminal sequence, Phe-X-Gly-Leu-Met-NH2, where X is either an Aromatic or an Aliphatic amino acid. The genes that produce tachykinins encode precursor proteins called preprotachykinins, which are chopped apart into smaller peptides by posttranslational proteolytic processing. The genes also code for multiple splice forms that are made up of different sets of peptides.

Physalaemin Chemical compound

Physalaemin is a tachykinin peptide obtained from the Physalaemus frog, closely related to substance P. Its structure was first elucidated in 1964.

Neurokinin 1 (NK1) antagonists (-pitants) are a novel class of medications that possesses unique antidepressant, anxiolytic, and antiemetic properties. NK-1 antagonists boost the efficacy of 5-HT3 antagonists to prevent nausea and vomiting. The discovery of neurokinin 1 (NK1) receptor antagonists was a turning point in the prevention of nausea and vomiting associated with cancer chemotherapy.

Neurokinin A Chemical compound

Neurokinin A (NKA), formerly known as Substance K, is a neurologically active peptide translated from the pre-protachykinin gene. Neurokinin A has many excitatory effects on mammalian nervous systems and is also influential on the mammalian inflammatory and pain responses.

Neurokinin B Chemical compound

Neurokinin B (NKB) belongs in the family of tachykinin peptides. Neurokinin B is implicated in a variety of human functions and pathways such as the secretion of gonadotropin-releasing hormone. Additionally, NKB is associated with pregnancy in females and maturation in young adults. Reproductive function is highly dependent on levels of both neurokinin B and also the G-protein coupled receptor ligand kisspeptin. The first NKB studies done attempted to resolve why high levels of the peptide may be implicated in pre-eclampsia during pregnancy. NKB, kisspeptin, and dynorphin together are found in the arcuate nucleus (ARC) known as the KNDy subpopulation. This subpopulation is targeted by many steroid hormones and works to form a network that feeds back to GnRH pulse generator.

Gastric inhibitory polypeptide receptor

The gastric inhibitory polypeptide receptor (GIP-R), also known as the glucose-dependent insulinotropic polypeptide receptor, is a protein that in humans is encoded by the GIPR gene. GIP-R is a member of the 7-transmembrane protein family, a class of G protein

Tachykinin receptor 1

The tachykinin receptor 1 (TACR1) also known as neurokinin 1 receptor (NK1R) or substance P receptor (SPR) is a G protein coupled receptor found in the central nervous system and peripheral nervous system. The endogenous ligand for this receptor is Substance P, although it has some affinity for other tachykinins. The protein is the product of the TACR1 gene.

Gastrin-releasing peptide receptor

The gastrin-releasing peptide receptor (GRPR), now properly known as BB2 is a G protein-coupled receptor whose endogenous ligand is gastrin releasing peptide. In humans it is highly expressed in the pancreas and is also expressed in the stomach, adrenal cortex and brain.

Prolactin-releasing peptide receptor

The prolactin-releasing peptide receptor (PrRPR) also known as G-protein coupled receptor 10 (GPR10) is a protein that in humans is encoded by the PRLHR gene.

Tachykinin receptor 2

Substance-K receptor is a protein that in humans is encoded by the TACR2 gene.

Tachykinin receptor 3

Tachykinin receptor 3, also known as TACR3, is a protein which in humans is encoded by the TACR3 gene.

Neuropeptide FF receptor 2

Neuropeptide FF receptor 2, also known as NPFF2 is a human protein encoded by the NPFFR2 gene.

Trefoil factor 2

Trefoil factor 2 is a protein that in humans is encoded by the TFF2 gene.

TAC1

Preprotachykinin-1,, is a precursor protein that in humans is encoded by the TAC1 gene.

Prolactin-releasing peptide

Prolactin-releasing peptide (PrRP) is a peptide hormone that in humans is encoded by the PRLH gene. PrRP stimulates prolactin (PRL) release and regulates the expression of prolactin through binding to the prolactin-releasing peptide receptor (GPR10).

TAC4

Tachykinin-4 is a protein that in humans is encoded by the TAC4 gene.

Osanetant

Osanetant (developmental code name SR-142,801) is a neurokinin 3 receptor antagonist which was developed by Sanofi-Synthélabo and was being researched for the treatment of schizophrenia but was discontinued. It was the first non-peptide NK3 antagonist developed in the mid-1990s, Other potential applications for osanetant is in the treatment of drug addiction, as it has been found to block the effects of cocaine in animal models.

L-733,060

L-733,060 is a drug developed by Merck which acts as an orally active, non-peptide, selective antagonist for the NK1 receptor, binding with a Ki of 0.08 nM. Only one enantiomer is active which has made it the subject of several asymmetric synthesis efforts.

Vofopitant

Vofopitant (GR205171) is a drug which acts as an NK1 receptor antagonist. It has antiemetic effects as with other NK1 antagonists, and also shows anxiolytic actions in animals. It was studied for applications such as the treatment of social phobia and post-traumatic stress disorder, but did not prove sufficiently effective to be marketed.

References

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000166863 - Ensembl, May 2017
  2. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000025400 - Ensembl, May 2017
  3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. Bonner TI, Affolter HU, Young AC, Young WS (Jan 1988). "A cDNA encoding the precursor of the rat neuropeptide, neurokinin B". Brain Res. 388 (3): 243–9. doi:10.1016/0169-328x(87)90031-3. PMID   3479225.
  6. Page NM, Woods RJ, Gardiner SM, Lomthaisong K, Gladwell RT, Butlin DJ, Manyonda IT, Lowry PJ (Jul 2000). "Excessive placental secretion of neurokinin B during the third trimester causes pre-eclampsia". Nature. 405 (6788): 797–800. Bibcode:2000Natur.405..797P. doi:10.1038/35015579. PMID   10866201. S2CID   4392048.
  7. "Entrez Gene: TAC3 tachykinin 3 (neuromedin K, neurokinin beta)".

Further reading